Replimune Group, Inc.

REPLNASDAQBeobachtung

US$15.30

-3.2 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: USCEO: Sushil PatelEmployees: 465Market cap: 1.3 BIPO: 20/07/2018Web: www.replimune.com

Replimune Group, Inc. (REPL) ist im Bereich Healthcare / Biotechnology tätig und hat ihren Hauptsitz in Woburn, Massachusetts. Das Unternehmen konzentriert sich auf die Entwicklung von onkolytischen Immuno-Gen-Therapien, mit dem Ziel, das körpereigene Immunsystem zur Bekämpfung maligner Zellen zu aktivieren. Ein…

Brief assessment by a strategy agent, last updated on 03/08/2026. Not investment advice.

PRICE HISTORY

26/08/25+167.8 %26/08/26

1D

-3.7 %

1W

+2.7 %

1M

+76.3 %

6M

+85.5 %

YTD

+56.5 %

1Y

+167.8 %

2Y

+47.8 %

5Y

-51.6 %

10Y

–

EARNINGS

Next earnings date

05/11/2026 (in 71 days)

Volatility around earnings

~-33% stronger price swings than usual

SCORES

Valuation

Valued significantly cheaper than its own historical average.

Why this value? Details with Pro only.

Trend

Very strong uptrend.

Why this value? Details with Pro only.

Quality

Average balance sheet quality.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are selling significantly more shares than they buy.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Significantly more upgrades than downgrades from analysts recently.

Why this value? Details with Pro only.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Persistently high short volume ratio, partly with a Reg SHO threshold listing.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

4 credits free on registration
Access to virtual portfolios and watchlist
No credit card, no payment details needed
No subscription, no minimum term
Our own servers in Germany, no US cloud

Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT REPL

ANALYST ASSESSMENT

PRICE TARGET LOW

US$17.00

CONSENSUS

US$18.67

MEDIAN

US$19.00

PRICE TARGET HIGH

US$20.00

0

STRONG BUY

11

BUY

3

HOLD

1

SELL

0

STRONG SELL

15

TOTAL · Buy

DATE	ANALYST FIRM	RATING	ACTION
07/08/2026	Wedbush	Neutral → Outperform	upgrade
07/08/2026	JP Morgan	Overweight	maintain
04/08/2026	Leerink Partners	Market Perform → Outperform	upgrade
31/07/2026	Cantor Fitzgerald	Neutral → Overweight	upgrade
31/07/2026	Wedbush	Neutral	maintain
30/06/2026	Wedbush	Neutral	maintain
01/06/2026	Wedbush	Neutral	maintain
13/04/2026	Leerink Partners	Outperform → Market Perform	downgrade

METRICS

P/E

-4.86

P/B

14.02

EV/EBITDA

-4.16

RETURN ON EQUITY

-66 %

NET MARGIN

0 %

DEBT/EQUITY

1.06

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

93.7 %

FLOAT SHARES

78,731,279

AVG. DAILY VOLUME (30D)

6,373,896

INSIDER TRANSACTIONS (SEC)

DATE	INSIDER	ROLE	TRANSACTION	SHARES	PRICE	PLAN TYPE
24/08/2026	Astley-Sparke Philip	Director	Gift	50,000	0	Spontaneous
19/08/2026	Hill Emily Luisa	Officer	Sale	9,256	14.28	Spontaneous
12/08/2026	Schwendenman Andrew	Officer	Sale	7,632	12.97	Spontaneous
12/08/2026	Patel Sushil	Officer	Sale	39,341	12.97	Spontaneous
12/08/2026	Hill Emily Luisa	Officer	Sale	11,448	12.97	Spontaneous

Page 1 / 3

ATTENTION

Price since yesterday: -3.7%

Search (Google Trends)

19/0726/0703/08

INSTITUTIONAL HOLDERS

FUND / INSTITUTION	SHARES	CHANGE	AS OF
BAKER BROS. ADVISORS LP	11,045,336	+0	30/06/2026
BlackRock, Inc.	8,958,535	+2,719,296	30/06/2026
RTW INVESTMENTS, LP	7,411,581	+54,665	30/06/2026
Ridgeback Capital Investments L.P.	7,310,656	+7,310,656	30/06/2026
GOLDMAN SACHS GROUP INC	4,541,018	+2,263,742	30/06/2026

Page 1 / 3

Not investment advice. Past performance is not an indicator of future results.